| Adoptive Cell Transfer | ACT |
| Adverse Event | AE |
| Angiopoietin 2 | ANG2 |
| Antigen-Presenting Cell | APC |
| Barcelona Clinic HCC | BCLC |
| Chimeric Antigen Receptor T Cell | CAR-T Cell |
| Cytokine-Induced Killer Cell | CIK |
| Cytotoxic T-Lymphocyte | CTL |
| Cytotoxic T Lymphocyte-Associated Antigen 4 | CTLA-4 |
| Dendritic Cell | DC |
| Disease Control Rate | DCR |
| ECOG Performance Status | ECOG |
| Hepatocellular Carcinoma | HCC |
| Immune Checkpoints | ICPs |
| Intercellular adhesion molecule 1 | ICAM1 |
| Lymphocyte Activation Gene-3 | LAG-3 |
| Major Histocompatibility Complex Class 1 | MHC-1 |
| Median Time to Progression | mTTP |
| Monoclonal Antibody | mAb |
| Natural Killer Cell | NK |
| Notch pathway-related genes | NPRGs |
| Objective Response Rate | ORR |
| Overall Survival | OS |
| Programmed Cell Death 1 | PD-1 |
| Progression-Free Survival | PFS |
| Regulatory T Cell | Treg |
| Stem/progenitor cells | FLSPCs |
| T Cell Receptor | TCR |
| T-Cell Immunoglobulin Mucin-3 | TIM-3 |
| Transforming Growth Factor-Β | TGF-Β |
| Tumor-Associated Antigen | TAA |
| Tumor-Infiltrating Lymphocyte | TIL |
| Tumor-Associated Macrophage | TAM |
| Tumor Microenvironment | TME |